Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17698773 | 0.72 | NR3C2 (0.47) | BRD4CREBBP | |
| SCHEMBL17802065 | 0.69 | BRD4 (0.49) | BRD4CREBBP | |
| SCHEMBL16225464 | 0.68 | BRD4 (0.51) | BRD4CREBBP | |
| SCHEMBL16109961 | 0.68 | BRD4 (0.52) | BRD4CREBBP | |
| SCHEMBL16108386 | 0.68 | BRD4 (0.55) | BRD4CREBBP | |
| SCHEMBL16204664 | 0.68 | BRD4 (0.71) | BRD4CREBBP | |
| SCHEMBL16132522 | 0.67 | BRD4 (0.54) | BRD4CREBBP | |
| SCHEMBL16110932 | 0.67 | BRD4 (0.51) | BRD4CREBBP | |
| SCHEMBL17490356 | 0.66 | BRD4 (0.49) | BRD4CREBBP | |
| SCHEMBL18898320 | 0.66 | BRD4 (0.45) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160145248-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. (CA) | 2016-05-26 | — | — | US | disclosed |
| US-20160145248-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. (CA) | 2016-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145248-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | BRD4 1/4885CREBBP 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.